This company listing is no longer active
Global Blood Therapeutics Past Earnings Performance
Past criteria checks 0/6
Key information
-20.1%
Earnings growth rate
-12.1%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | 74.8% |
Return on equity | -272.4% |
Net Margin | -137.3% |
Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Global Blood Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 22 | 235 | -322 | 303 | 227 |
31 Mar 22 | 211 | -310 | 283 | 214 |
31 Dec 21 | 195 | -303 | 267 | 212 |
30 Sep 21 | 180 | -277 | 248 | 194 |
30 Jun 21 | 165 | -266 | 234 | 184 |
31 Mar 21 | 149 | -249 | 222 | 166 |
31 Dec 20 | 124 | -248 | 211 | 155 |
30 Sep 20 | 85 | -282 | 196 | 179 |
30 Jun 20 | 48 | -286 | 171 | 178 |
31 Mar 20 | 16 | -291 | 147 | 180 |
31 Dec 19 | 2 | -267 | 117 | 175 |
30 Sep 19 | 0 | -220 | 88 | 146 |
30 Jun 19 | 0 | -199 | 71 | 140 |
31 Mar 19 | 0 | -182 | 57 | 136 |
31 Dec 18 | 0 | -174 | 51 | 131 |
30 Sep 18 | 0 | -166 | 46 | 127 |
30 Jun 18 | 0 | -152 | 43 | 114 |
31 Mar 18 | 0 | -135 | 38 | 100 |
31 Dec 17 | 0 | -117 | 31 | 88 |
30 Sep 17 | 0 | -103 | 27 | 76 |
30 Jun 17 | 0 | -95 | 24 | 72 |
31 Mar 17 | 0 | -89 | 22 | 66 |
31 Dec 16 | 0 | -82 | 20 | 61 |
30 Sep 16 | 0 | -71 | 20 | 52 |
30 Jun 16 | 0 | -65 | 16 | 49 |
31 Mar 16 | 0 | -58 | 13 | 43 |
Quality Earnings: 0IVZ is currently unprofitable.
Growing Profit Margin: 0IVZ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0IVZ is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.
Accelerating Growth: Unable to compare 0IVZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0IVZ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-16.7%).
Return on Equity
High ROE: 0IVZ has a negative Return on Equity (-272.44%), as it is currently unprofitable.